4,5-diiodo-2-methyl-aniline | 860572-94-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4,5-diiodo-2-methyl-aniline
• 英文别名: 4,5-Dijod-2-methyl-anilin；4.5-Dijod-2-amino-toluol；4,5-Diiodo-2-methylaniline
• CAS: 860572-94-7
• 化学式: C₇H₇I₂N
• 分子量: 358.948
• InChiKey: ZQEWFQSLHMORFY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4,5-diiodo-2-methyl-aniline 生成 2,4,5-三碘甲苯
  参考文献：
  名称：

  Wheeler, American Chemical Journal, 1910, vol. 44, p. 140,500

  摘要：

  DOI：
• 作为产物：
  描述：

  4-碘-2-甲基苯胺 在 碘 、 溶剂黄146 作用下， 生成 4,5-diiodo-2-methyl-aniline
  参考文献：
  名称：

  Wheeler, American Chemical Journal, 1910, vol. 44, p. 501

  摘要：

  DOI：

文献信息

• RADIOSENSITIZER COMPOUNDS FOR USE IN COMBINATION WITH RADIATION
  申请人：LU Qing-Bin

  公开号：US20150343059A1

  公开（公告）日：2015-12-03

  Disclosed herein are radiosensitizer compounds useful in combination with radiation therapy, e.g., a synergistic combination therapy for the treatment of cancer and other disorders. The radiosensitizer compounds have the general formula I: wherein A represents an aromatic core; at least one of R a and R b is an electron transfer promoter as defined herein, e.g., NH 2 ; and at least one of R c is a leaving group as defined herein, e.g., halogen; and the remainder of the molecule is as defined herein. Pharmaceutical compositions, methods, uses, kits and commercial packages comprising the radiosensitizer compounds are also disclosed.
• NON-PLATINUM-BASED ANTI-CANCER COMPOUNDS FOR USE IN TARGETED CHEMOTHERAPY
  申请人：LU Qing-Bin

  公开号：US20160235743A1

  公开（公告）日：2016-08-18

  Disclosed herein are non-platinum-based (NPB) anti-cancer compounds useful for targeted chemotherapy, e.g., to generate anti-cancer effects for the treatment of cancer and other disorders while having no or minimal toxicity. The compounds N have the general formula I: (I) wherein A represents an aromatic core; at least one of R a and R b is an electron transfer promoter as defined herein, e.g., NH 2 ; and at least one of R c is a leaving group as defined herein, e.g., halogen; and the remainder of the molecule is as defined herein. Pharmaceutical compositions, methods, uses, kits and commercial packages comprising the anti-cancer compounds are also disclosed.
• US9655965B2
  申请人：——

  公开号：US9655965B2

  公开（公告）日：2017-05-23